 | | Vol. 12.13 – 16 April, 2021 |
| |
|
|
| Researchers discovered that CREB1 played a central role in maintaining new luminal cell survival and that oncogenesis dramatically changed the CREB1-induced transcriptome. CREB1 was active in luminal cells, but not basal cells.
[Oncogene] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that photoactivated 3 very efficiently eliminated both prostate bulk, differentiated, and prostate, hardly treatable cancer stem cells simultaneously and with similar efficiency.
[Chemistry-A European Journal] |
|
|
|
| Downregulation of miR-215 was correlated with overexpression of KDM1B in enzalutamide-resistant prostate cancer cells, which promoted AR-dependent AGR2 transcription and regulated the sensitivity to next-generation AR-targeted therapy.
[Cancer Gene Therapy] |
|
|
|
| Scientists measured the effect of the CLK inhibitor, the benzothiazole TG003, on two prostate cancer cell lines. TG003 reduced cell proliferation and increased apoptosis in PC3 and DU145 cells.
[Scientific Reports] |
|
|
|
| Neuroendocrine prostate cancer (NEPC) diagnosis is challenging as available markers are not sufficiently specific. Investigators identified novel, extracellular vesicles-based biomarkers for diagnosing NEPC.
[Scientific Reports] |
|
|
|
| Using osteoblasts as a model system, scientists observed that prostate cancer cells and their conditioned medium could stimulate and increase mineralization and osteoblasts’ differentiation.
[Biology] |
|
|
|
| Researchers determined which prostate-specific membrane antigen (PSMA)-binding peptide among peptides 563, 562 and 9-mer, showed the highest selectivity towards PSMA using 22Rv1 prostate cancer cells, a cell line with moderate PSMA levels.
[Amino Acids] |
|
|
|
| Scientists characterized the radiobiological effects induced by Radium-223 and evaluated its kinetics on metastatic prostate cancer cells.
[International Journal of Radiation Biology] |
|
|
|
|
| The authors focus on recent progress made in prostate cancer, including the role of protein arginine methyltransferase 5 (PRMT5) in the androgen receptor expression and signaling and DNA damage response, particularly DNA double-strand break repair.
[Cancer Gene Therapy] |
|
|
|
|
| LIDDS AB announced that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy.
[LIDDS AB] |
|
|
|
| PROCEPT® BioRobotics Corporation announced that Blue Cross Blue Shield of Massachusetts and EmblemHealth are now providing insurance coverage for Aquablation therapy delivered by the AquaBeam® Robotic System for the treatment of benign prostatic hyperplasia
[PROCEPT® BioRobotics Corporation] |
|
|
|
|
|
|
|
| | Memorial Sloan Kettering – New York, New York, United States |
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
| | University of Calgary – Calgary, Alberta, Canada |
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
| |
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
